Bristol-Myers Squibb Co (NYSE:BMY) was the recipient of a large decline in short interest in March. As of March 15th, there was short interest totalling 65,779,147 shares, a decline of 11.2% from the February 28th total of 74,111,887 shares. Based on an average daily volume of 21,684,195 shares, the short-interest ratio is presently 3.0 days. Approximately 4.0% of the company’s shares are short sold.
BMY has been the topic of several research reports. Bank of America dropped their price objective on shares of Bristol-Myers Squibb from $53.00 to $51.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 19th. BMO Capital Markets boosted their price objective on shares of Bristol-Myers Squibb to $62.00 and gave the company an “outperform” rating in a report on Wednesday, March 20th. Zacks Investment Research cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Thursday, January 3rd. Credit Suisse Group reaffirmed a “hold” rating and set a $59.00 target price on shares of Bristol-Myers Squibb in a report on Friday, February 15th. Finally, Edward Jones cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Friday, January 4th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and seven have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $58.50.
A number of hedge funds have recently added to or reduced their stakes in BMY. Bank of New York Mellon Corp raised its stake in shares of Bristol-Myers Squibb by 1.6% in the third quarter. Bank of New York Mellon Corp now owns 17,123,173 shares of the biopharmaceutical company’s stock valued at $1,063,006,000 after acquiring an additional 277,927 shares during the period. Martingale Asset Management L P increased its position in Bristol-Myers Squibb by 12.7% during the 3rd quarter. Martingale Asset Management L P now owns 556,353 shares of the biopharmaceutical company’s stock valued at $34,540,000 after purchasing an additional 62,836 shares during the period. Rafferty Asset Management LLC purchased a new position in Bristol-Myers Squibb during the 3rd quarter valued at about $207,000. Standard Life Aberdeen plc increased its position in Bristol-Myers Squibb by 9.9% during the 3rd quarter. Standard Life Aberdeen plc now owns 533,866 shares of the biopharmaceutical company’s stock valued at $33,143,000 after purchasing an additional 48,146 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Bristol-Myers Squibb by 32.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 237,744 shares of the biopharmaceutical company’s stock valued at $14,751,000 after purchasing an additional 58,445 shares during the period. Institutional investors and hedge funds own 74.28% of the company’s stock.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.09. Bristol-Myers Squibb had a net margin of 21.95% and a return on equity of 48.99%. The firm had revenue of $5.97 billion during the quarter, compared to analyst estimates of $5.95 billion. During the same quarter in the prior year, the business earned $0.68 earnings per share. Bristol-Myers Squibb’s revenue for the quarter was up 9.6% on a year-over-year basis. As a group, research analysts predict that Bristol-Myers Squibb will post 4.16 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be given a dividend of $0.41 per share. The ex-dividend date is Thursday, April 4th. This represents a $1.64 annualized dividend and a yield of 3.68%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 41.21%.
TRADEMARK VIOLATION WARNING: This news story was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.baseballdailydigest.com/news/2019/04/24/short-interest-in-bristol-myers-squibb-co-bmy-drops-by-11-2.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Featured Story: Why does the United States have a lingering trade deficit?
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.